Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Leerink Partners Cuts Price Target on Amicus Therapeutics (FOLD) Following FDA Feedback

Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease

November 28, 2016 4:09 PM EST

Regulatory Plan for Full Approval Pathway Based on Generation of Additional Gastrointestinal Symptoms Data

Intermediate Expanded Access Program Expected to Begin in 2017

Conference Call Today at 4:30pm ET

CRANBURY, N.J., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announces its planned regulatory pathway to collect additional data to support full approval for the oral... More